NCT07626346 Dexmedetomidine as an Adjuvant to Bupivacaine in Ultrasound-guided Pericapsular Nerve Group Block( PENG)
| NCT ID | NCT07626346 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kasr El Aini Hospital |
| Condition | Shoulder Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 84 participants |
| Start Date | 2026-06-10 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 84 participants in total. It began in 2026-06-10 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients are greatly concerned about pain that occurs shortly after shoulder surgeries. Most patients experience significant pain after shoulder surgery, with almost half reporting severe pain immediately after. Since shoulder surgeries are usually done as outpatient or one day procedures, good pain control after surgery is important for quick recovery and rehab for patient's overall recovery. Interscalene nerve blocks provide the best pain relief for shoulder surgery patients. They reduce pain for at least 8 hours and decrease the need for opioids for 8 to 12 hours after surgery. It anesthetizes most of the brachial plexus, except the ulnar nerve (C8-T1). It is useful for surgeries on the distal clavicle, shoulder, and proximal humorous .However, interscalene blocks also raise concerns about temporary and potential long-term problems with breathing, especially paralysis of the diaphragm and phrenic nerve. By targeting nerve roots in the neck rather than peripheral nerves, interscalene blocks also carry a higher risk of nerve damage.The pericapsular nerve group block has been effectively used in hip surgeries as in hip arthroplasty and it is one of the best regional anesthesia regarding many other hip operations. Recently PENG block has also shown to have strong analgesic effect on shoulder surgeries. Dexmedetomidine (DEX) is a highly selective Alpha-2 adrenergic agonist. It has sedative and analgesic properties that thought to be due to binding to both presynaptic and postsynaptic alpha-2 adrenoreceptors and inhibiting the release of norepinephrine, as a result, it terminates the propagation of pain signals and inhibits the sympathetic activity decreasing heart rate and blood pressure. The aim of our study is to compare the effect of adding dexmedetomidine to bupivacaine in ultrasound-guided Pericapsular nerve group block (PENG) with bupivacaine alone and determine its effect on duration of analgesia and post-operative opioid consumption.
Eligibility Criteria
Inclusion Criteria: 1. Male or female patients aged 18-65 years 2. Patients Undergoing laparoscopic shoulder surgeries (shoulder arthroplasties and shoulder endoscopic surgeries ) 3. American Society of Anesthesiologists (ASA) physical status I-II Exclusion Criteria: 1. Patient refusal. 2. hypersensitivity or contraindication to dexmedetomidine 3. History of allergy or intolerance to study medications 4. Chronic opioid use (\>3 months) 5. Pregnancy or breastfeeding 6. Severe renal or hepatic impairment 7. Patient's with coagulopathy disorders
Contact & Investigator
Nasr Abdallah, Professor
STUDY DIRECTOR
anesthesia department , cairo university
Frequently Asked Questions
Who can join the NCT07626346 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Shoulder Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07626346 currently recruiting?
Yes, NCT07626346 is actively recruiting participants. Contact the research team at nabihomar100@yahoo.com for enrollment information.
Where is the NCT07626346 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07626346 clinical trial?
NCT07626346 is sponsored by Kasr El Aini Hospital. The principal investigator is Nasr Abdallah, Professor at anesthesia department , cairo university. The trial plans to enroll 84 participants.